Open AccessClinical Outcomes among Patients with Drug-resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens
Author(s) -
R R Kempker,
Lali Mikiashvili,
Ying Zhao,
David Benkeser,
Ketevan Barbakadze,
Nino Bablishvili,
Zaza Avaliani,
Charles A. Peloquin,
Henry M. Blumberg,
Maia Kipiani
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz1107
Subject(s) - bedaquiline , medicine , sputum culture , regimen , clofazimine , interquartile range , culture conversion , tuberculosis , sputum , adverse effect , mycobacterium tuberculosis , immunology , leprosy , pathology
Bedaquiline and delamanid are newly available drugs for treating multidrug-resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no comparison studies.